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Summanry Analysis of human tumour-denrved cell lines has previously resulted in the identification of novel
transformation-related elements and provided a useful tool for functional studies of different genes. To
establish the utility of such cell lines as indicators of change relevant to urothelial cancer, we have charac-
terised the expression of five genes (p53. MDM2, Rb, E-cadherin, APC) within a panel of human bladder
carcinoma cell lines. Using single-strand conformation polymorphism (SSCP) and direct sequencing, p53
mutations were identified in 7 15 (47%0) cell lines reflecting events reported in bladder tumours. Immunohis-
tochemical analysis of p53 in cultured cells and in paraffin-embedded sections of xenografts from the cell line
panel revealed discordant results. An absence of p53 nuclear staining was associated with an exon 5 mutation
in EJ and with multiple p53 mutations found in J82. Two cell lines positive for p53 staining in the absence of
detectable mutation displayed overexpression of MDM2 (PSI, HT1197) in Western blot analysis. Loss or
aberrant Rb expression was recorded in 5 15 (TCCSUP, SCaBER, 5637, HT1376, J82) cell lines. Absence of
E-cadherin was recorded in 5 15 cell lines (TCCSUP, EJ, KK47, UM-UC-3, J82) with loss of m-catenin in
immunoprecipitated E-cadherin complexes of CUBIII. Western blot analysis of APC revealed a truncated
protein in 1 15 (CUBIII) cell lines. The characterisation of oncogenic events within this panel qf human
bladder carcinoma cell lines establishes a representation of change observed in bladder tumours and better
defines the genotypic background in these experimental human cell models of neoplastic progression.
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The hypothesis that neoplastic transformation results from
an accumulation of genetic alterations in a cell over time is
accepted as the molecular framework underlying neoplastic
progression. A significant number of genetic alterations have
been demonstrated in urothelial neoplasia, including H-ras
(Fujita et al., 1985; Visvanathan et al., 1988; Czerniak et al.,
1990; Knowles and Williamson, 1993; Levesque et al., 1993),
p53 (Sidransky et al., 1991; Fujimoto et al., 1992), retinoblas-
toma (Rb; Horowitz et al., 1990; Cairns et al., 1991; Cordon-
Cardo et al., 1992; Logothetis et al., 1992), c-erbB-2 (Wright
et al., 1990, 1991; Coombs et al., 1991; Moriyama et al.,
1991; Wood et al., 1991; Sauter et al., 1993), epidermal
growth factor receptor (EGFR; Neal et al., 1985, 1990), c-src
(Fanning et al., 1992), MDM2 (Habuchi et al., 1994; Lianes
et al., 1994) and MTS1 (Cairns et al., 1994; Kamb et al.,
1994; Spruck et al., 1994).
It has become clear that a series of diverse genetic changes
are involved in generating the different phenotypes observed
in bladder cancer. However, how these different genetic
elements interact with other cellular proteins and complement
each other in neoplastic progression is little understood. To
address these issues, investigators have developed both in
vitro and in vivo models of progression, including the use of
human carcinoma derived cell lines. Such cell lines have been
used as a resource to identify the involvement of change at a
particular locus in specific tissues (Der et al., 1982; Parada et
al., 1982; Horowitz et al., 1990; Fanning et al., 1992) and in
studies directed at identifying the function of a gene follow-
ing restoration of expression (Takahashi et al., 1991; Good-
rich et al., 1992). It is argued that changes found in cell lines
are not always a reflection of events in vivo; however,
molecular events associated with H-ras, Rb and c-src (Der et
al., 1982; Horowitz et al., 1990; Fanning et al., 1992, respec-
tively) were first identified in a panel of bladder cell lines and
later confirmed to be altered in bladder tumour tissue. In this
study we have characterised the expression of different genes
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implicated in carcinogenesis within a panel of human bladder
carcinoma cell lines.
Materials and methds
Cell lines
5637, CUBIII, EJ, HT1376, HU456, J82, KK47, PSI, RT4,
RT112, TCCSUP, UM-UC-3, HT1197, SCaBER (ATCC)
and BC16 (kindly provided by Dr C Remikoff, University of
Wisconsin) cell lines were maintained in Dulbecco's modified
medium supplemented with 7.5% fetal bovine serum and
penicillin/streptomycin.
Immunoprecipitation
MDM2 Subconfluent cells were washed in phosphate-
buffered saline (PBS), lysed in ice-cold PBSTDS lysis buffer
(PBS pH 7.4, 1% Triton X-100, 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulphate, 100 U ml- aprotinin) for
20 min and clarified by centrifuging at 14 000g for 20 min at
4'C. Protein for the immunoprecipitations was standardised
using the BCA method (Pierce, Rockford, IL, USA) and
incubated overnight at 4°C with 15jil of anti-MDM2 (Ab-1;
Oncogene Science, Manhasset, NY, USA) followed by the
addition of protein A-Sepharose beads for an additional
90 min incubation at 4°C. Immunocomplexes were washed
three times in PBSTDS and once in 0.1% PBS. Samples were
run on a 7.5% polyacrylamide gel and proteins were transfer-
red to nitrocellulose. Blots were blocked overnight at 4°C in
10% non-fat dried milk in triethanolamine-buffered saline
(TBS) with 0.05% Tween-20 followed by incubation with
MDM2 (Ab-1; Oncogene Science) for 2 h at room
temperature. The blots were washed three times with TBST
followed by incubation with a horseradish peroxidase-
coupled second antibody. After additional washes in TBST,
blots were developed using an ECL Kit (Amersham, Arling-
ton Heights, IL, USA).Oncogenic events in human bladder carcinoma cell lines
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E-cadherin and .4PC Confluent cells were washed in PBS.
lysed in hot sample buffer (0.08 m Tris pH 6.8. 0.1 m dithioth-
reitol. 0.07 Mi SDS. 100o glycerol. 0.001%o bromophenol blue
plus 1 m-M calcium chloride for E-cadhenrn) and boiled for
5 mmn. Identical dishes were l-sed and assayed for protein
concentration using the BCA method (Pierce). After standar-
disinz for protein. samples were run on a modified 300o agarose
zel for APC (Smith et al.. 1993) or a 7.50O polyvacrylamide gel
(E-cadhenn) and transferred to PVDF (APC) or nitrocellulose
(E-cadhenn) membranes. APC blots were blocked in 10oo
non-fat milk in TBST overnight at 4'C. incubated with APC-l
(Oncozene Science). for 2 h. washed three times in TBST.
incubated with a horseradish peroxidase-coupled second
antibodv for 1 h. w-ashed again w-ith several changes of TBST
and developed with an ECL kit (Amersham). E-cadherin blots
were blocked for 5 h in a buffer consisting of 50°o non-fat milk
and 10o bovine serum albumin in PBS containing 1 m-Nt
calcium chloride. then incubated with HECD-1 (Z-med
Laboratories. San Francisco. CA. USA) overnight at 4°C. The
blots were washed in 0.10O Tween-20 in PBS calcium chloride
and then in PBS calcium chloride onlv. three times for 15 min
each. Thev were next incubated with a horseradish peroxidase-
coupled second antibody for 30 min in the blockinz solution.
The blots w-ere washed as above. then developed with an ECL
kit.
Immunoprecipitation ofE-cadherin andp53 from
l-? S]methionine-labelled cells
Subconfluent dishes of cell lines were incubated in
methionine-free Dulbecco's modified Eagle medium
(DMEM) for I h before labelling. Cells were labelled for
40 min for p53 or for 4 h for E-cadherin in the presence of
[ SJmethionine (100 pCi ml-') in methionine-free medium
supplemented with 30o dialysed fetal calf serum. The cells
were washed in PBS and lxsed in 1 ml of PBSTDS for pSi3 or
in a buffer containing 20 mm Tris-HCI pH 7.4. 150 m-
sodium chloride. 2 mm calcium chloride. 1 mm phenvlmethxl-
sulphonyl fluoride. 20o Triton X-100 and 50pgml1 leupep-
tin for E-cadherin. They w-ere then precleared. equalised for
protein and incubated with HECD-1 for E-cadherin (Zymed
Laboratories). or p53 Ab-l (Oncogene Science) overnight at
4°C. Protein A beads were added and immunocomplexes
u-ere washed as described above. Following electrophoresis.
gels u-ere stained. destained, dried onto filter paper and
exposed to film.
Rev-erse transcription-polvmnerase chain reaction RT-PCR
for E-cadherin
Bladder cell line first-strand cDNA w-as prepared by reverse
transcnption of total RNA (SuperScript. Gibco BRL.
Gaithersburg. MD. USA). Tu-o separate regions were
amplified. usinz primer pairs Ex7-rExl0 2 and Ex9
2A-rExl 1 (Becker et al.. 1994). First-strand cDNA was
subjected to 40 cycles of PCR (94'C for 1 min. 55'C for
1 min. 72'C for I min) in 20 p1 of solution [10 mm Tris-HCI
pH 8.3. 50mm potassium chloride. 1.9 mm magnesium
chloride. 200 pMi each dATP. dGTP. dCTP and dTTP.
600ng each of 5' and 3' primers and 1.0 unit of Taq
polymerase (Perkin-Elmer)]. PCR products were visualised by
agarose gel electrophoresis.
ImmunohistochenistrY
For paraffin-based immunohistochemistry. 5 x 106 cells were
injected subcutaneouslv into the flanks of nude mice.
Tumour growvths were fixed in formalin for 24 h and embed-
ded in paraffin for sectioning. Cell lines were groxkn on slides
and fixed with acetone-methanol (50 50). Cells on slides and
tissue sections were incubated with the human p53-specific
mouse monoclonal antibodies Ab-2 and Ab-6 (1:2100.
Oncogene Science) u-hich recognise both wild-type and
mutant human p53 protein. Bound IgG was detected by the
aidin-biotin and horseradish peroxidase methods using a
Vectastain Elite avidin -biotin complex kit (Vector
Laboratories. Burlingame. CA. USA). Detection of p53 uwas
scored by a pathologist for intensity and distribution of
staining using HT29 as a positive control. Specimens u-ere
scored positive x-hen > lO0o of the cells or tumour shou-ed
nuclear staining.
DNA amplification
High molecular wxeight DNNA was prepared by proteinase K
dieestion follow ed bx phenol-chloroform extraction (Leves-
que et al.. 1993). Exons 4. 5. 6 and 8 of the p53 gene u-ere
individually amplified by a standard PCR reaction. with
initial denaturation at 94TC for S min followved by 30 cycles
of amplification (942C for 15 s: 562C for 30 s: 722C for 30 s)
and a final extension step at 7'^C for 7 min. The PCR
conditions for exon 7 w-ere identical except for an annealing
temperature of 60'C. Reactions w-ere performed in 25 Al mix-
tures containing 50 mm potassium chloride. 10 mNi Tris-HCI
(pH 8.3). 1.75 mxt magnesium chloride. 200pMt each dATP.
dCTP. dTTP. dGTP. 900 ng of each pnrmer and 1.25 units of
Taq DNA polvmerase per sample. The primers used for PCR
were as follow-s:
Exon 4 upstream
5'-TCTTTTTCACCCATCTACAGTCC-3'
Exon 4 dow-nstream
5'-GCCCCTCAGGGC.tACTGACCGTGCA-3'
Exon 5 upstream
5'-CCTTCCTCTTCCTACACAGTAC-3'
Exon S dow-nstream
5'-CCCAGCTGCTCACCATCGCT-3'
Exon 6 upstream
5'-GAGAGACGACAGGGCTGGTT-3'
Exon 6 downstream
5'-AGTTGC.VAACCAGACCTCAGGC-3'
Exon 7 upstream
5'-CCTCATCTTGGGCCTGTGTT-3'
Exon 7 dow-nstream
5'-TCAGCGGCAAGCAGAGGCTG-3'
Exon 8 upstream
5'-CCTTACTGCCTCTTGCTTC-3
Exon 8 dou-nstream
5'-TGAATCTGAGGCAT.-ACTGC-3'
Exon 9 upstream
5'-GGAATTCTTGCCTCTTTCCTAGCA-3'
Exon 9 downstream
5'-GGAATTCCCAAGACTTAGTACCTG-3'.
PCR-SSCP
The conditions for SSCP w-ere similar to those described for
routine PCR except that 1 p1 of [32P]dCTP was added per
reaction. Each sample >-as evaluated by electrophoresis at
two separate predefined conditions. Two microlitres of PCR
product was mixed with 8 p1 of 95% formamide. 20 mm
EDTA. 0.05%0 bromophenol blue and 0.05% xylene cyanol
and heated at 95°C. Three microlitres of this solution was
quickly loaded onto either an 8% polyacrylamide gel with no
glycerol or a 60,'o polyacry-lamide gel with 10% glycerol.
Electrophoresis was performed at 40 W for 2.5 h at 4°C or at
30 W for 5-6 h at room temperature with constant fan cool-
ing. respectivelv. Gels wvere dried on filter paper and exposed
to X-ray film with an intensifying screen at - 80°C for
1-12h.
Direct sequencing
For sequence determination of samples showing mobilitx-
shifts. amplified DNA fragments were run on a 1.5% agarose
ethidium bromide gel. Qiaex extracted (Qiagen. Chatswvorth.
CA. USA) and directly sequenced by a modified dideoxv-
nucleotide method w-ith Sequenase Version 2.0 (United States
Biochemical Corporation. Cleveland. OH. USA) using both
the downstream and upstream primers.mcu wobi hol Muir c.d bus
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Identification ofp53 mutations
Analysis of the p53 gene was initially conducted using single-
strand conformation polymorphism (SSCP) following
amplification of individual exons 4-9. Figure 1 shows
representative SSCP gels from exons 5 and 8 demonstrating
aberrant migration of amplified product in bladder cell lines
EJ (Figure la, lane 12) and 5637 (Figure lb, lane 5). Direct
sequencing of PCR products confirmed the presence of a
mutation in each of these cases (Figure 2) and in alternative
exons (Figure 2b) where aberrant migration was detected in
SSCP. The presence of wild-type p53, defined in SSCP, was
also confirmed by direct sequencing (Figure 2c). Within the
cell panel 7/15 (47%) cell lines harboured p53 mutations in
exons 4, 5, 7, 8 and 9 (Table I). Three p53 point mutations
were found in one cell line, J82, two in exon 8 and one in
exon 9. Transversion and transition mutation events were
equally represented within this group.
Expression ofp53 in bladder cell lines
The levels of p53 protein within the cell panel were initially
established in Western blot analyses, in which detectable
levels of p53 were found only in cell lines harbouring a
known mutation (data not shown). To determine whether the
absence of p53 protein in this assay was indicative of loss of
expression or reflects low-level expression not detected by this
technique, we immunoprecipitated p53 from radiolabelled
cell lysates of bladder carcinoma cell lines. In all cell lines
p53 protein was detected, displaying a range of labelling
a A.
15
Fugwe 1 SSCP analysis of exon 5 (a) and exon 8 (b) of p53 in
bladder carcinoma cel lines. (a) Exon 5: lane 1, HT1376; lane 2,
DLD-1 non-denatured; lane 3, DLD-I; lane 4, KK47; lane 5,
HTI 197; lane 6, CCL 233-positive control; lane 7, 5637; lane 8,
CUBIII; lane 9, BC16; lane 10, RT4; lane 11, HU456; lane 12,
El; lane 13, RT112; lane 14, PSI. (b) Exon 8: lane 1, CCL 222
non-denatured; lane 2, CCL 222; lane 3, CCL 235-negative cont-
rol; lane 4, HT29-positive control; lane 5, 5637; lane 6, HTI 197;
lane 7, BCC16; lane 8, RT4; lane 9, HU456; lane 10, El; lane 11,
RT112; lane 12, PSI; lane 13, CUBIII; lane 14, KK47; lane 15,
HT1376. Open arrowheads represent migrational level of
amplified products in positive controls harbouring known p53
mutational changes. The solid arrowheads denote altered prod-
ucts in bladduer cell lines.
intensity and migrational properties in SDS-polyacrylamide
gel electrophoresis (Figure 3). With the exception of EJ
(Figure 3, lane 9) all cell lines harbouring known p53 muta-
tions displayed distinct, strongly labelled p53 protein prod-
ucts. Similar labelling intensity of p53 was observed in PSI
despite the absence of detectable mutation in molecular
analysis. Cell line TCCSUP repeatedly displayed a p53 pro-
tein migrating more rapidly than wild-type p53, possibly
reflecting the presence of a molecular change outside the
exons screened in this study.
Detection ofoverexpression ofp53protein in
immwtocytochemistry
The rationale for using p53 immunostaining in tumours is
based upon the accumulation of p53 protein owing to the
extended half-life of the protein conferred by the presence of
a mutation. Although available antibodies recognise both
wild-type and mutant p53 protein, the limitations of sen-
sitivity associated with this technique result in the lack of
detection of wild-type p53 because of low levels of expres-
sion. To evaluate this hypothesis in bladder carcinomas we
performed p53 immunostaining within the panel of cell lnes
in culture and in paraffin-embedded sections of tumours
generated from these cells in nude mice. Initial evaluation of
two p53 antibodies, MAb 1801 and MAb DOI, showed
a
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Fugwe 2 p53 sequence from exon 5 (a), exon 7 (b) and exon 8
(c). In each case the mutation is marked by an asterisk with
normal sequence from an alternative bladder cell line shown on
the right The mutant/normal (left/right) sequence pairs shown in
(a) are EJ and RT112 exon 5, (b) CUBIlI and RT4 exon 7 and
(c) 5637 and TCCSUP exon 8.
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Table I Summary of oncogenic events recorded in a panel of human bladder carcinoma cell lines
p53 exons 4- 9
Cell IHCO
line cells tumour Exon Codon Amino acid change MDM2 Rb E-cadherin Catenins' APC
BC16 + NT NDd + + + a,py FL
TCCSIP - NT ND + - - FL
CUBITI + + 7 241 Ser (TCC) ->Phe (TTC) + + + P.y TRUN
EJ -- 5 164 Lys (AAG) ->Glu (GAG) + + - FL
UM-UC-3 + + 4' 113 Phe (TTC) ->Cys (TGC) + + - FL
RT4 (+-)- ND' + + + xA.y FL
RTI12 - - ND + + + (,,y FL
SCaBER + - 4 110 Arg (CGT) ->Leu (CT[) + - + ,Ay FL
5637 + + 8c 280 Arg (AGA) ->Thr (ACA) + - + ,X,y FL
PSI + -NDY ++++ + + X7.y FL
KK47 -- ND + + - FL
HU456 (+ -)- ND + + + a.P.y FL
HT1376 (+ -)- 7 250 Pro (CCC) ->Leu (CTC) + - + a.p. FL
HT1197 + - ND + +++ + + a,P-7 FL
J82 8 271 Glu (GAG) ->Lys (AAG) + +f - FL
-NT 8 274 Val (GTT) ->Phe (TM)
9 320 Lys (AAG)- > Asn (AAC)
aIHC. immunohistochemistry of cells grown on slides and paraffin-embedded sections of tumours generated from these cell lines. Cells on
slides: + -represents staining in 50% of cells. Paraffin-embedded sections: + represents > 10% staining. - represents < 10% staining. NT,
non-tumorigenic. bCatenin status was assessed by immunoprecipitation of the E-cadherin complex in radiolabelled cell lysates. 'FL, full length;
TRLTUN truncated protein. 'ND. No mutation detected in exons 4-9. 'Polymorphism detected in exon 4, codon 72, of p53 = Arg (CGC)
- >Pro (CCC). 'Aberrant Rb product recorded in immunoprecipitates (Horowitz et al.. 1989).
Figure 3 Immunoprecipitation of p53 from radiolabelled lysates
of bladder carcinoma cell lines. Lane 1, PSI; lane 2, HT1 197; lane
3, HT1376; lane 4, RT4; lane 5, TCCSUP; lane 6, CUBIII; lane
7, HU456; lane 8, RT112; lane 9, EJ; lane 10, KK47. Arrowhead
denotes migrational level of wild-type p53 protein.
greater sensitivity for nuclear staining with DO! in both assay
systems. Staining of cells grown on slides revealed strong
nuclear staining in 10 of 15 cell lines, five ofwhich harboured
known p53 mutations in exons 4, 7 and 8. Of the remaining
five, one cell line (BC16) was immortalised by Simian virus
40, which is known to associate with and stabilise the p53
protein. Cell lines PSI and HTI 197 showed strong nuclear
staining in all cells, while RT4, HT1376 and HU456 dis-
played distinct staining in approximately 50% of the cells.
Interestingly, two cell lines harbouring p53 mutations, EJ
and J82, revealed no detectable nuclear staining with either
p53 antibody. Repetition of these experiments in paraffin-
embedded tumour sections from 12 cell lines which grew as
xenografts in nude mice revealed detectable nuclear staining
in three (CUBIII, 5637, UM-UC-3) of nine which showed
staining of cells in culture. Tumour tissue derived from
HT1376 displayed very weak limited nuclear staining (<5%
of the cells) which was scored as negative in this study, in
which > 10% staining was used to record a positive staining
reaction.
Expression ofMDM2 and Rb in bladder cell lines
It is known that functional inactivation of wild-type p53 can
be effected by association with alternative cellular proteins
including MDM2. To assess the possible involvement of
MDM2 in bladder cancer, we performed Western blot
analysis on MDM2-immunoprecipitated protein-standardised
cell lysates to establish the level of expression of the MDM2
protein in cell lines. Figure 4 shows immunoprecipitation/
Western blot analysis from a representative number of cell
lines demonstrating overexpression of the 90 kDa MDM2
protein in HT1197 and PSI (Figure 4, lanes 3 and 6 respec-
tively). In both cases p53 nuclear staining was detected in
Figre 4 Western blot analysis of MDM2 in immunoprecip-
itated protein-standardised cell lysates from bladder cell lines.
Lane 1, BC16; lane 2, HT1376; lane 3, HT1197; lane 4, KK47;
lane 5, RT112; lane 6, PSI; lane 7, UM-UC-3; lane 8, 5637; lane
9, TCCSUP. Overexpression of MDM2 (90kDa) observed in
HTI 197 and PSI. Molecular weight markers 116 and 95 kDa
shown.
cells in the absence of detectable mutational change (Table
I).
Loss of expression of the Rb gene product has been
identified as a late-stage event in urothelial neoplastic pro-
gression associated with the invasive phenotype. The status
of Rb in bladder carcinoma cell lines has previously been
addressed, noting both loss and mutation of Rb protein
product (Horowitz et al., 1989, 1990). Extension of this
observation to include additional bladder cell lines confirmed
loss of Rb expression associated with TCCSUP, SCaBER,
HT1376 and 5637, and aberrant migration of Rb in cell line
J82 following immunoprecipitation (data not shown). No
additional gross changes were recorded in Rb using
immunoprecipitation or Western blot analysis (Table I).
E-cadherin/catenin complex
Recent publications have indicated loss or reduction of E-
cadherin expression associated with late-stage bladder
tumours (Bringuier et al., 1993). To establish the status of
E-cadherin expression and associated catenins in bladder cell
lines, we employed a number of different experimental app-
roaches. Figure 5a shows Western blot analysis of protein-
standardised cell lysates from the panel of human bladder
carcinoma cell lines probed with E-cadherin antibody. Five
of 15 cell lines showed absence of detection of E-cadherin
protein (EJ, J82, KK47, TCCSUP, UM-UC-3) in repeated
- .65Oncogenic events in human bbadder carcinoma cell lines
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assays. To confirm that this represents loss of E-cadherin
expression rather than lack of antibody recognition. we per-
formed RT-PCR using two different primer sets spanning
exons 7-11 of the cDNA sequence. In all five tumour cell
lines lacking detectable E-cadherin protein. no amplified
product was generated in RT-PCR. suggesting a lack of
message (Figure Sb). The presence of the E-cadherin protein
is not synonymous with functionality. especially since we
know of the requirement for catenin association in this com-
plex. To address this issue we immunoprecipitated E-
cadherin from radiolabelled lysates of cell lines. Figure Sc
shows a representative autoradiograph demonstrating the
absence of precipitable protein in EJ and KK47 consistent
with Western blot analysis and RT-PCR. a loss of x-catenin
associated with E-cadherin in CUBIII (lane 2) and reduced
representation of A-catenin in BC16 (lane 3). Eight of the 15
cell lines showed a normal E-cadherin catenin protein profile
in this assay. Lack of detection of cm-catenin in CUBIII could
result from the loss of expression of the protein or possible
mutation preventing association. Using RT-PCR with a sin-
gle set of primers amplifying a 1500bp cDNA showed the
presence of a-catenin message in all cell lines (data not
shown).
a
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Figure 5 (a) Western blot analysis of protein-standardised total
cell lvsates from human bladder cell lines probed with anti-E-
cadherin. Lane 1. RT4: lane 2. PSI: lane 3. BC16; lane 4. J82;
lane 5. HT1376; lane 6. EJl lane 7. CUBIII: lane 8. HTI 197: lane
9. HU456: lane 10. TCCSU-P: lane 11. RTI 12: lane 12. SCaBER:
lane 13. KK47; lane 14. 5637: lane 15. UM-UC-3. (b) RT-PCR
of E-cadherin in the panel of human bladder cell lines. Lane 1.
BC16: lane 2. CUBIII: lane 3. EJ: lane 4. HT1197: lane 5.
HT1376: lane 6. HU456: lane 7. J82: lane 8. KK47: lane 9. PSI:
lane 10. RT4: lane 11. RT112: lane 12. SCaBER: lane 13. UM-
UC-3: lane 14. water control. Primers for cDNA span exons
7 10. generating a 545 bp fragment. Size markers shown on
right. (c) Immunoprecipitation of E-cadherin from metabolicalhv
labelled Iysates including representative members of the bladder
cell panel. Lane 1. EJ: lane 2. CUBIII: lane 3. BC16: lane 4.
KK47: lane 5. RT4. Stars show migrational lesel of E-cadhenn
(approximately 124 kDa). i-catenin (approximatelv 102 kDa).
catenin (approximatelv 97 kDa) and y-catenin (approximatelv
92 kDa). Note absence of E-cadherin and associated proteins in
EJ (lane 1) and KK47 (lane 4). the absence of precipitable
x-catenin in CUBIII (lane 2) and reduced 0-catenin representa-
tion in BC16 (lane 3). Molecular weeight markers 116 and 95 kDa
show-n.
Expression ofthe adenomatous poltiposis coli gene (APC)
The .4PC zene encodes for a 312 kDa protein which has
recently been reported to be associated wvith the E-cadherin
complex. specifically A-catenin (Rubinfeld er al.. 1993: Su et
al.. 1993). although the significance of this is not vet evident.
Using a modified Western blot procedure on total cell lysates
from the panel of bladder carcinoma cell lines. CUBIII
repeatedly displayed a truncated APC protein of approx-
imately 130 kDa (Figure 6. lane 3). The remaining 14 bladder
carcinoma cell lines presented a full-length APC protein in
this assay system.
Discussion
In this report we have characterised the expression of five
genes implicated in urothelial neoplastic progression (p53.
MDM2. Rb. E-cadherin. APC) within a panel of 15 human
bladder carcinoma cell lines. Such cell lines have preViously
been used to identifv molecular events involved in bladder
cancer, including ras (Der et al.. 1982; Parada et al.. 1982)
and c-src activation (Fanning et al.. 1992). loss of Rb expres-
sion (Horowitz et al.. 1990) and more recently to establish
the tumour-suppressive nature of specific genetic elements
implicated in neoplastic progression (Takahashi et al.. 1991;
Goodrich et al.. 1992). As we learn more about the function
of different molecules and their interrelationships, it is impor-
tant to know the genotypic background of cell lines in order
to be able to interpret more fully phenotypic changes
associated with the introduction of different genes. In addi-
tion. the knowledge of molecular events characteristic of
different cell lines provides an opportun'ty to assess the
sensitivitv of different assay systems used in detecting specific
molecular changes. In this study w-e have attempted to add-
ress these issues.
Within the bladder cell panel. p53 mutations were detected
in 7 15 (470/O) lines using SSCP and confirmed in direct
sequence analysis. identifying nine point mutation events
within exons 4. 5. 7. 8 and 9 With three p53 mutations found
in the J82 cell line. Within this group transition transversion
events were equally represented with no deletion or inser-
tional changes recorded: these results were consistent With
previous findings in human bladder tumours (Sidransky et
al.. 1991: Fujimoto et al.. 1992: Williamson et al.. 1994).
Immunoprecipitation revealed the presence of p53 in all cell
lines with migrational differences apparent between wild-type
and some mutant p53 proteins including TCCSUP. in which
no mutation was detected in molecular analyses. Of course.
alteration of the p53 gene in TCCSUP could be present
outside of the exons evaluated in this study.
Ten of 15 cell lines showed strong nuclear staining with
p53 antibodies MAb 1801 and MAb DO1 including 5 7 har-
bouring known p53 mutations, with J82 and EJ the excep-
tions. More surprisingly, we detected distinct nuclear staining
in approximately 50o of cells in three lines in culture
(HU456. HT1376. RT4). two of which (HU456. RT4) dis-
played no apparent p53 mutations in molecular or
biochemical analyses. Strong nuclear staining was also
,t4P£ ee
Figure 6 Western blot analysis of total cell lIsates probed with
anti-APC antibodv. Lane 1. CCL 228-truncated APC control of
147 kDa: lane 2. EJ-full-length APC of 312 kDa. lane 3. CUBIII:
lane 4. HTI 197: lane 5. RT1 12; lane 6. RT4: lane 7. no lvsate
control: lane 8. J82; lane 9. KK47; lane 10. RT4; lane 11. 5637.
lane 12. TCCSUP. Arrow denotes migrational lesel of full-length
APC protein. Molecular weight marker (200 kDa) shows the
truncated APC protein in CUBIII is approximatelv 130kDa.
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observed in PSI and HT1197. consistent with the finding of
overexpression of MDM2 in these cell lines. Twelve of 15 cell
lines within the panel were tumorigenic and established as
xenografts in nude mice. Only three of nine paraffin-
embedded tumour sections showed p53 nuclear staining
similar to that observed in cultured cells. These three.
CUBIII. UM-UC-3 and 5637, all harbour p53 mutations.
HT1376 also showed weak (<5% cells) nuclear staining in
restricted tumour regions. In a series of 14 colon carcinoma
cell lines processed in this way, all retained detectable nuclear
p53 staining in paraffin-embedded sections of xenografts.
Hence. these results do not reflect a lack of methodological
sensitivity. rather they may be accounted for by the type of
p53 mutations found in these different epithelia. Consistent
with this idea we have recorded nuclear p53 staining in
approximately 35% of bladder tumours, contrasting with
70% of colon carcinomas, despite the molecular data which
supports similar frequencies of p53 mutations in tumours
from these tissues (Esrig et al.. 1993. 1994). Similar findings
were recently reported in a study of 243 bladder tumours
(Esrig et al.. 1994), which confirmed the prognostic potential
of p53 staining in bladder cancer lesions (Sarkis et al.. 1993:
Soini et al.. 1993).
Contrasting with a recent publication (Habuchi et al..
1994: Lianes et al., 1994). no p53 nuclear staining was
observed in tumour sections from HT1197 or PSI which were
shown to overexpress MDM2 in vitro. Possible explanations
for this include modulation of MDM2 expression in vivo.
lack of association of p53 with MDM2 in these cell lines or
masking of epitopes following processing of tissue, given that
the previous studies were performed on frozen tissue sections
(Lianes et al.. 1994). It is clear from our studies that
immunocytochemical staining of p53 in bladder tumours.
using either MAb 1801 or MAb DOI, underestimates the
frequency of p53 mutations.
One previous study has reported loss of E-cadherin expres-
sion in one of three bladder cell lines (Frixen et al., 1991), a
finding reported to be associated with late-stage bladder
tumours (Bringuier et al.. 1993). In the present study, loss of
E-cadherin protein was observed in 5 of 15 bladder cell lines
(33%) in which absence of E-cadherin message was estab-
lished using RT-PCR. The molecular events leading to this
loss of expression are presently uncharacterised, but it is
interesting to note that BC16, a cell line immortalised by
SV40. shows marked reduction of E-cadherin expression
levels.
Expression of E-cadherin is not synonymous with func-
tionality. and loss of x-catenin in the precipitated E-cadherin
complex can contribute to the absence of calcium-dependent
aggregation (Breen et al., 1993). Lack of detectable a-catenin
in CUBIII E-cadherin complexes was found in the presence
of cx-catenin message and may be attributable to a mutation
at this locus preventing complexing. Recently, APC has also
been shown to be associated with the E-cadherin complex
co-precipitating with P-catemnn (Rubinfeld et al., 1993; Su et
al., 1993). Whether the presence of a truncated APC protein
in CUBIII impinges upon the integrity of the E-cadherin
complex is not known, but it does not account for the lack of
m-catemn since this component is present in E-cadherin-
precipitable complexes in alternative cell lines known to har-
bour a truncated APC protein (unpublished observations).
The high incidence of loss of E-cadherin expression in blad-
der cell lines (33%) correlates well with the in vivo findings
(Bringuier et at.. 1993) and provides a valuable tool for the
study of cellular and molecular events associated with the
disruption of this gene. Whether the findings of a truncated
APC protein in one cell line is indicative of its involvement in
bladder cancer is unclear but should be viewed in the context
of a previous study in which 75% of human colon cell lines
displayed a truncated APC product in this assay, contrasting
with 40 additional cell lines derived from breast, cervical,
pancreatic, lung and prostatic cancer, in which only the
full-length APC protein was detected (Smith et al., 1993).
This experimental approach does not account for the pos-
sibility of more subtle APC mutations in bladder tumours.
but previous results argue that alterations resulting in trunca-
tion of the APC protein are not common events associated
with the in vitro establishment of human cell lines (Smith et
al.. 1993). To establish this observation as relevant in human
bladder cancer, screening of human tumour material will be
necessary.
The use of human tumour-derived cell lines from different
organs has previously led to the identification of molecular
events relevant to specific tumour lesions. In addition, such
cell panels have proven useful in the investigation of the role
of different tumour-suppressor genes following introduction
of either mutant or wild-type elements into cell lines lacking
expression of the protein (Takahashi et al., 1991; Goodrich et
al., 1992). There is also considerable evidence that such cell
panels retain molecular changes representative of events
specific to the organ of interest. An example of this is the
finding of the loss of Rb expression in bladder cell lines,
which is not found in a similar panel of human colon
carcinoma-derived cell lines, consistent with observations
recorded in these tumour types in vivo. Tumour suppression
following restoration of Rb expression is thus dependent on
the recipient cell line used (Bookstein et al., 1990; Takahashi
et al.. 1991; Muncaster et al.. 1992). This may not be a direct
reflection of organ specificity but may possibly be due to
background genotypic differences. which may in turn be
rooted in organ-specific molecular pathways of neoplastic
transformation. If such panels of human cell lines are to
continue to be useful in these approaches it is necessary to be
aware ofmultiple genetic parameters which may influence the
results recorded. In this study we have demonstrated the
limitations in sensitivity of p53 immunostaining when per-
formed in paraffin-embedded sections of bladder tissue and
attribute this partly to the specific p53 mutations recorded in
bladder tumours. Although alterations associated with the
p53 gene continue to be a potentially useful prognostic
indicator in bladder cancer, it is clear that immunocyto-
chemistry alone will detect only a proportion of such
changes.
The changes recorded within the bladder cell panel used in
this study are consistent with events reported in bladder
lesions and have proven to be a good indicator of specific
genetic changes involved in human bladder cancer. Although
it is clear that the frequency of specific changes found in
bladder cell lines should not be considered indicative of the
frequency of such events in tumours (Cairns et al.. 1994;
Spruck et al., 1994), they nonetheless continue to be useful
tools in the study of urothelial neoplastic progression. With
the characterisation of additional changes associated with
these bladder cell lines we are now better equipped to inves-
tigate the functional significance of different genetic changes
in urothelial neoplastic progression using this human cell
model.
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